| Original language | English (US) |
|---|---|
| Pages (from-to) | 1690-1693 |
| Number of pages | 4 |
| Journal | Kidney International Reports |
| Volume | 7 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2022 |
Keywords
- TIMP2∗IGFBP7
- insulin-like growth factor binding protein-7
- methotrexate
- nephrotoxicity
- neutrophil gelatinase-associated lipocalin (NGAL)
- tissue inhibitor metalloproteinase-2
ASJC Scopus subject areas
- Nephrology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Kidney International Reports, Vol. 7, No. 7, 07.2022, p. 1690-1693.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - A Prospective Evaluation of Novel Renal Biomarkers in Patients With Lymphoma Receiving High-Dose Methotrexate
AU - Barreto, Jason N.
AU - Kashani, Kianoush B.
AU - Mara, Kristin C.
AU - Rule, Andrew D.
AU - Lieske, John C.
AU - Giesen, Callen D.
AU - Thompson, Carrie A.
AU - Leung, Nelson
AU - Witzig, Thomas E.
AU - Barreto, Erin F.
N1 - Funding Information: The authors thank Ms. Holly A. Thorson and the Mayo Clinic Clinical Research Trials Unit staff for their assistance with patient enrollment and sample collection. This project was supported in part by the Hematology Oncology Pharmacy Association Foundation Research Grant Program (JNB), the CTSA Grant Number UL1 TR002377 from the National Center for Advancing Translational Science (JNB), and the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number K23AI143882 (EFB). Its contents are solely the authors' responsibility and do not necessarily represent the official views of the National Institutes of Health. Funding Information: The authors thank Ms. Holly A. Thorson and the Mayo Clinic Clinical Research Trials Unit staff for their assistance with patient enrollment and sample collection. This project was supported in part by the Hematology Oncology Pharmacy Association Foundation Research Grant Program (JNB), the CTSA Grant Number UL1 TR002377 from the National Center for Advancing Translational Science (JNB), and the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number K23AI143882 (EFB). Its contents are solely the authors' responsibility and do not necessarily represent the official views of the National Institutes of Health. The deidentified data supporting this study's findings are available on request from the corresponding author. The data are not publicly available owing to privacy or ethical restrictions. JNB, KBK, KCM, ADR, JCL, CDG, CAT, NL, TEW, and EFB wrote the manuscript. JNB, KBK, KCM, ADR, JCL, CAT, NL, TEW, and EFB designed the research. JNB, KBK, KCM, ADR, CDG, and EFB performed the research. JNB, JMR, JNB, KBK, KCM, ADR, JCL, CDG, CAT, NL, TEW, and EFB analyzed the data. JNB, KBK, KCM, ADR, JCL, CDG, CAT, NL, TEW, and EFB played an important role in interpreting the results.
PY - 2022/7
Y1 - 2022/7
KW - TIMP2∗IGFBP7
KW - insulin-like growth factor binding protein-7
KW - methotrexate
KW - nephrotoxicity
KW - neutrophil gelatinase-associated lipocalin (NGAL)
KW - tissue inhibitor metalloproteinase-2
UR - http://www.scopus.com/inward/record.url?scp=85127887535&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127887535&partnerID=8YFLogxK
U2 - 10.1016/j.ekir.2022.03.013
DO - 10.1016/j.ekir.2022.03.013
M3 - Article
AN - SCOPUS:85127887535
SN - 2468-0249
VL - 7
SP - 1690
EP - 1693
JO - Kidney International Reports
JF - Kidney International Reports
IS - 7
ER -